Core Insights - Revolution Medicines and Iambic Therapeutics have entered a multi-year technology and research collaboration to develop novel drug candidates using Iambic's AI-driven discovery platform [1][2][4] - Iambic will utilize structures and molecular libraries from Revolution Medicines to train custom versions of its NeuralPLexer model for protein-ligand structure prediction [2][7] - The collaboration includes a financial component where Iambic could receive up to $25 million in upfront and milestone payments, along with ongoing R&D reimbursements [4][7] Company Overview - Revolution Medicines is focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes RAS(ON) inhibitors currently in clinical development [8] - Iambic Therapeutics, founded in 2020, leverages AI technology to address complex drug discovery challenges and has a pipeline of clinical assets targeting unmet patient needs [6][8] Technology and Collaboration Details - The collaboration aims to enhance drug discovery capabilities by integrating Iambic's AI models with Revolution Medicines' proprietary data, allowing for rapid exploration of challenging oncology targets [3][5] - Iambic's AI-driven platform, including the NeuralPLexer and PropANE models, is designed to optimize lead selection and drug properties through advanced molecular predictions [5][6]